How I treat patients with thrombotic thrombocytopenic purpura: 2010

Blood

Volumn 116, Issue 20, 2010, Pages 4060-4069

  George, James N ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CREATININE; HYPERTENSIVE FACTOR; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; BLEEDING; CATHETER COMPLICATION; CATHETER OCCLUSION; CATHETER REMOVAL; COMA; CONCENTRATION LOSS; CONFUSION; COUGHING; CREATININE BLOOD LEVEL; DEATH; DIARRHEA; DISEASE EXACERBATION; DISEASE REGISTRY; DRUG MEGADOSE; DYSPNEA; ENZYME ACTIVITY; ENZYME DEFICIENCY; FATIGUE; FEVER; HEADACHE; HEART ARREST; HELLP SYNDROME; HEMATOCRIT; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOTENSION; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALIGNANT HYPERTENSION; MEDICAL DOCUMENTATION; MEMORY DISORDER; NAUSEA; NEOPLASM; PATIENT CARE; PLASMAPHERESIS; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REVIEW; SEIZURE; STROKE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VEIN THROMBOSIS; VOMITING; WEAKNESS;

EID: 78549253211     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-271445     Document Type: Review

References (62)

1. Kaushansky K. How I treat: a new style of clinical review article. Blood. 2000;96(4):1205. (Pubitemid 30658444)
2. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96(4):1223-1229.
3. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45(2):139-159.
4. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365(9464):1073-1086.
5. Laszik ZG, Silva FG. Hemolytic uremic syndrome, thrombotic thrombocytopenia purpura, and other thrombotic microangiopathies and coagulopathies. In: Jennett JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's Pathology of the Kidney. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:699-762.
6. Waters AM, Kerecuk L, Luk D, et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr. 2007;151(2):140-144.
7. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol. 2008;3:249-277.
8. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-1687.
9. Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy for diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687-696.
10. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature. Medicine. 1981;60(6):413-428. (Pubitemid 12207235)
11. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6):393-397.
12. Rock GA, Shumak KH, Kelton JG, et al. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion. 1992;32(8):710-714.
13. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11-18.
14. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1511.
15. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med. 1998;339(22):1578-1584. (Pubitemid 28536132)
16. Tsai HM, Lian ECY. Antibodies to von-Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585- 1594.
17. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;101(1):60-68.
18. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494. (Pubitemid 32938741)
19. Terrell DR, Williams LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS13 deficiency. J Thromb Haemost. 2005;3(7):1432-1436.
20. Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol. 2010;85(11):844-847.
21. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant. 2001;27(6):641-646.
22. Siami K, Kojouri K, Swisher KK, Selby GB, George JN, Laszik ZG. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation. 2008;85(1):22-28.
23. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic hematopoietic stem cell transplantation: a diagnostic dilemma. Transfusion. 2004;44:294-304.
24. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(8):571-575. (Pubitemid 41001631)
25. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplantation-associated microangiopathy (TAM): results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95-100.
26. George JN. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder. Bone Marrow Transplant. 2008;41(11):917-918.
27. McMinn JR, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apher. 2001;16(4):202-209.
28. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2003;10(5):339-344.
29. Gottschall JL, Elliot W, Lianos E, McFarland JG, Wolfmeyer K, Aster RH. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood. 1991;77(2):306-310.
30. Gottschall JL, Neahring B, McFarland JG, Wu G-G, Weitekamp LA, Aster RH. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol. 1994;47(4):283-289. (Pubitemid 24372282)
31. Stroncek DF, Vercellotti GM, Hammerschmidt ED. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood. 1992;80(1):241-248.
32. Aster RH. Quinine sensitivity: a new cause of the hemolytic uremic syndrome. Ann Intern Med. 1993;119(3):243-244.
33. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med. 2001;135(12):1047-1051. (Pubitemid 33151026)
34. Karpac CA, Li X, Terrell DR, et al. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol. 2008;141(5):696-707. (Pubitemid 351667636)
35. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354(18):1927-1935.
36. George JN, Vesely SK, James JA. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J. 2007;100(5):512-514.
37. George JN, Vesely SK, Terrell DR. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol. 2004;41(1):60-67.
38. Francis KK, Kojouri K, George JN. Occult systemic carcinoma masquerading as thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Commun Oncol. 2005;2(4):339-343.
39. Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 cases and a systematic review of the literature. Oncologist. 2007;12(1):11-19. (Pubitemid 46143499)
40. Swisher KK, Doan JT, Vesely SK, et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura: report of five patients with a systematic review of the literature. Haematologica. 2007;92(7):936-943.
41. Benjamin M, Terrell DR, Vesely SK, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis. 2009;48(8):1129-1137.
42. Clark WF, Garg AX, Blake PG, Rock GA, Heidenhwim AP, Sackett DL. Effect of awareness of a randomized controlled trial on use of experimental therapy. JAMA. 2003;290(10):1351-1355. (Pubitemid 37442632)
43. Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura. Transfusion. 2007;48(2):382-392.
44. Ridolfi RL, Hutchins GM, Bell WR. The heart and cardiac conduction system in thrombotic thrombocytopenic purpura: a clinicopathologic study of 17 autopsied patients. Ann Intern Med. 1979;91(3):357-363.
45. Brain MC, Dacie JV, Hourihane OB. Microangiopathic hemolytic anemia: the possible role of vascular lesions in pathogenesis. Br J Haematol. 1962;8(4):358-374.
46. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589-600.
47. Rizvi MA, Vesely SK, George JN, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion. 2000;40(8):896-901.
48. McMinn JR, Thomas IA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: an additional study of 78 consecutive patients. Transfusion. 2003;43(3):415-416.
49. Howard MA, Williams LA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: III. An additional study of 57 consecutive patients, 2002-2005. Transfusion. 2006;46(1):154-156.
50. Nguyen L, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura: IV. An additional study of 43 consecutive patients, 2005-2008. Transfusion. 2009;49(2):392-394.
51. Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion. 2009;49(5):873-887.
52. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103(11):4043-4049.
53. Scully MF, Cohen H, Cavenagh JD, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS13. Br J Haematol. 2006;136(3):451-461.
54. Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol. 2009;84(7):418-421.
55. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmakonetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201-1208.
56. Nguyen L, Li X, Duvall D, Terrell DR, Vesely SK, George JN. Efficacy of twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura. Transfusion. 2007;48(2):349-357.
57. Cataland SR, Jin M, Ferketich AK, et al. An evaluation of ciclosporine and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2007;132(1):146-149. (Pubitemid 44912601)
58. Vesely SK, Li X, McMinn JR, Terrell DR, George JN. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion. 2004;44(8):1149-1158. (Pubitemid 38989747)
59. Howard MA, Duvall D, Terrell DR, et al. A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the six year experience of the Oklahoma TTP-HUS Study Group. J Clin Apher. 2003;18(1):16-20. (Pubitemid 36535060)
60. Ambadwar P, Duvall D, Wolf NJ, Terrell DR, Vesely SK, George JN. Support groups for patients who have recovered from thrombotic thrombocytopenic purpura. J Clin Apher. 2008;23(5):168-169.
61. Lewis QF, Lanneau MS, Mathias SD, Terrell DR, Vesely SK, George JN. Long-term deficits in health-related quality of life following recovery from thrombotic thrombocytopenic purpura. Transfusion. 2009;49(1):118-124.
62. Kennedy KA, Lewis QF, Scott JG, et al. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion. 2009;49(6):1092-1101.